Duds his 4C predictions for Nuheara on the "good short" thread were so uninformed I wouldn't be going near any of his predictions with a barge pole. He worked out the cash position for Nuheara but failed to include $1.5m from oppies conversions and had no idea a R & D refund was due. Pretty basic stuff to miss.
- Forums
- ASX - By Stock
- NUH
- Ann: NUH Expands Health Research in Auditory Processing Disorders
Ann: NUH Expands Health Research in Auditory Processing Disorders, page-66
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NUH (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.75M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NUH (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online